VivoSeq
Oncology

Gastrointestinal Stromal Tumor

82

Pipeline Programs↗

18

Active Trials↗

43

Companies Involved↗

Gastrointestinal Stromal Tumor is a moderately active landscape with 82 programs across 43 companies. The most active players are Daiichi Sankyo, Blueprint Medicines, Kura Oncology, Inc.. 6 therapies are approved with 12 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

68/100

Pipeline Velocity

19/100

Mech. Concentration

8/100

Completion Rate

75/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Daiichi Sankyo logo

Daiichi Sankyo

2 programs

Phase 1B

Blueprint Medicines

1 program

Phase 1K

Kura Oncology, Inc.

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2P

Prism Pharmaceuticals

2 programs

Phase 2Amgen logo

Amgen

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

82%

Small molecule

70 of 85 classified programs — the dominant modality here.

18%ALL OTHERSMonoclonal antibody78%Protein / enzyme56%RNA therapy11%Cell therapy11%Gene therapy11%

Small molecule leads; the ring shows all 85 classified programs, each share of the total. Modality classified for 100% of 86 pipeline programs.

Analysis

Trial Status

123

clinical trials

Completed69 · 56%
Terminated18 · 15%
Unknown status9 · 7%
Active, not recruiting8 · 7%
Recruiting8 · 7%
Withdrawn5 · 4%
Other6 · 5%

Clinical Trials

Trial Activity

123 trials

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
Recruiting·CCentre Leon Berard·Phase 2·NCT05152472·110 enrolled
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT04933669·122 enrolled
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Recruiting·GSK logoGSK·Phase 3·NCT07218926·450 enrolled
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Recruiting·—·Phase 2·NCT05905887·48 enrolled
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Recruiting·—·Phase 2·NCT05385549·35 enrolled
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Recruiting·KKura Oncology, Inc.·Phase 1·NCT06655246·157 enrolled
Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
Recruiting·UUniversity of California, San Diego·Phase 1·NCT07171203·18 enrolled
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
Recruiting·DDeciphera Pharmaceuticals, LLC·Phase 1/2·NCT06630234·120 enrolled
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT00265798·38 enrolled
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Active, not recruiting·—·Phase 2·NCT03556384·23 enrolled
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Active, not recruiting·CCogent Biosciences, Inc.·Phase 3·NCT05208047·442 enrolled
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT01991379·75 enrolled
Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients With Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-Deficient Gastrointestinal Stromal Tumor (GIST)
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT04595747·48 enrolled
PRISM-3: Regorafenib in Refractory GIST
Active, not recruiting·Bayer logoBayer·Phase 3·NCT06800003·350 enrolled
INTRIGUE Extension: Ripretinib vs Sunitinib in GIST
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 3·NCT04610671·453 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)